Department of Health
and Human Services (HHS)
and Human Services (HHS)
July 7, 2020
PAR-20-111 - Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
National Institute of Neurological Disorders and Stroke (NINDS)
The purpose of this notice is to clarify the Application Types Allowed for PAR-20-111 "Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional). The Activity Code section (Part 1. Overview Information) has been modified to remove the following text "U44Small Business Innovation Research (SBIR) Cooperative Agreements - Phase II". This text is being removed to be consistent with Section II. Award Information stating that only New (Fast-Track) applications will be accepted in response to this Funding Opportunity Announcement (FOA). This change will be effective for the August 11, 2020 receipt date and subsequent due dates.Changes to the FOA are shown below.
Currently Reads:
Part 1. Overview Information
| Activity Code | U44Small Business Innovation Research (SBIR) Cooperative Agreements - Phase II U44Small Business Innovation Research (SBIR) Cooperative "Agreement – Fast Track" |
Modified to Read:
Part 1. Overview Information
| Activity Code |
U44Small Business Innovation Research (SBIR) Cooperative "Agreement – Fast Track" |
All other aspects of this FOA remain unchanged.
Charles Cywin, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-1779
Email:charles.cywin@nih.gov